Products
Albutrepenone acog alfa was approved in many countries and in the EU in 2016 as a powder and solvent for the preparation of a solution for injection for intravenous use (Idelvion).
Structure and properties
Albutrepenonacog alfa is a recombinant fusion protein consisting of recombinant blood clotting factor IX combined with recombinant albumin. It is produced by biotechnological methods.
Effects
Albutrepenonacog alfa (ATC B02BD04) replaces blood clotting factor IX, which is required for blood clotting, and its fusion with albumin results in longer half-life, longer dosing interval, and higher systemic exposure.
Indications
For prevention and treatment of bleeding in previously treated patients with hemophilia B (congenital factor IX deficiency), including control and prevention of bleeding during surgical procedures.
Dosage
According to the SmPC. The drug is administered as an intravenous infusion.
Contraindications
Albutrepenone acog alfa is contraindicated in case of hypersensitivity. For complete precautions, see the drug label.
Interactions
Drug-drug interactions are not known.
Adverse effects
The most common possible adverse effects include headache.
